CRISPR/Cas therapeutic strategies for autosomal dominant disorders

Autosomal dominant disorders present unique challenges, as therapeutics must often distinguish between healthy and diseased alleles while maintaining high efficiency, specificity, and safety. For this task, CRISPR/Cas remains particularly promising. Various CRISPR/Cas systems, like homology-directed repair, base editors, and prime editors, have been demonstrated to selectively edit mutant alleles either by incorporating these mutations into sgRNA sequences (near the protospacer-adjacent motif [???near the PAM???]) or by targeting a novel PAM generated by the mutation (???in the PAM???). However, these probability-based designs are not always assured, necessitating generalized, mutation-agnostic strategies like ablate-and-replace and single-nucleotide polymorphism editing. Here, we detail recent advancements in CRISPR therapeutics to treat a wide range of autosomal dominant disorders and discuss how they are altering the landscape for future therapies.

Automated summary

This article details recent advancements in CRISPR therapeutics for treating a wide range of autosomal dominant disorders and discusses how these advancements are shaping the future of therapies.